Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
Authors
Keywords
Bone metastases, Breast cancer, Denosumab, Osteonecrosis of the jaw, Prostate cancer, Zoledronic acid
Journal
SUPPORTIVE CARE IN CANCER
Volume 24, Issue 1, Pages 447-455
Publisher
Springer Nature
Online
2015-09-02
DOI
10.1007/s00520-015-2904-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
- (2014) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Precision Oncology in Breast Cancer: Better than Ever, or Less than Before?
- (2013) Adam Brufsky Breast Journal
- A Case of an Unusual Subtrochanteric Fracture in a Patient Receiving Denosumab
- (2013) Rodis Paparodis et al. Endocrine Practice
- Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis
- (2013) Lydia Gedmintas et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
- (2013) Matthew R. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
- (2013) Dino Amadori et al. LANCET ONCOLOGY
- Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy
- (2012) Stephanie T. Chang et al. BONE
- P4-13-01: Pain Severity and Analgesic Use Associated with Skeletal-Related Events in Patients with Advanced Breast Cancer and Bone Metastases.
- (2012) L Fallowfield et al. CANCER RESEARCH
- Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors
- (2012) S. Doshi et al. CLINICAL CANCER RESEARCH
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- (2012) Allan Lipton et al. EUROPEAN JOURNAL OF CANCER
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
- (2011) Matthew R Smith et al. LANCET
- Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors
- (2010) N. Simon Tchekmedyian et al. CANCER INVESTIGATION
- Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2010) Mark G. Kris et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
- (2009) Jean-Jacques Body et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates
- (2009) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
- (2008) Ana O Hoff et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
- (2008) R. G. G. Russell et al. OSTEOPOROSIS INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More